Apogee Therapeutics, Inc.
APGE
Updated: 24/09/2026, 08:34:07
Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life to treat AD, and APG808, a similarly formulated SQ extended half-life mAb targeting COPD. Furthermore, its earlier-stage pipeline features APG990, another SQ extended half-life mAb designed for AD, and APG222, comprising extended half-life subcutaneous antibodies also aimed at AD. Established in 2022, the company maintains its headquarters in Waltham, Massachusetts.
No summaries found.
- Share price
- $135.07
- Market cap
- $8.36B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Michael Thomas Henderson
- Employees
- 261
- IPO date
- 14/07/2023
- Beta
- 0.343
- Last dividend
- $0.00
- Day range
- $135.07 – $135.07
- 52-week range
- $35.39 – $135.09
- 1-day performance
- 0.00%
- 1-year performance
- 281.66%
- Current drawdown (1Y)
- -0.01%
- CIK
- 0001974640
- CUSIP
- 03770N101
- ISIN
- US03770N1019
- Created
- 07/12/2025, 02:06:54
- Last update
- 24/09/2026, 08:34:07
Track Apogee Therapeutics, Inc. with an AI analyst
See which prediction-market events move APGE, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Apogee Therapeutics, Inc. (APGE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Seeking Alpha • STOCK • 10/06/2026, 17:52:09
Apogee Therapeutics, Inc. (APGE) Discusses Positive Part B Results From Phase 2 APEX Trial of Zumilokibart in Atopic Dermatitis Transcript
Seeking Alpha • STOCK • 01/06/2026, 18:54:05
Apogee Therapeutics to Participate in Upcoming June Conferences
GlobeNewsWire • STOCK • 28/05/2026, 18:01:00
Apogee Therapeutics: Charging Toward Pivotal Eczema Trial With Extended Dosing
Seeking Alpha • STOCK • 28/05/2026, 17:01:16
Apogee Therapeutics Announces Positive 16-Week Part B Induction Dose Optimization Results from Phase 2 APEX Trial of Zumilokibart in Moderate-to-Severe Atopic Dermatitis
GlobeNewsWire • STOCK • 27/05/2026, 08:30:00
Apogee Therapeutics to Host Conference Call to Report Part B 16-Week Data from the Phase 2 APEX Trial of Zumilokibart in Patients with Moderate-to-Severe Atopic Dermatitis on May 27, 2026
GlobeNewsWire • STOCK • 26/05/2026, 18:01:00
Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $403 Million
GlobeNewsWire • STOCK • 26/03/2026, 17:01:00
Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering
GlobeNewsWire • STOCK • 24/03/2026, 22:53:00
APGE Stock Up as Skin Disease Drug Shows Sustained 52-Week Efficacy
Zacks Investment Research • STOCK • 24/03/2026, 12:31:07
Apogee Therapeutics, Inc. (APGE) Discusses 52-Week Phase 2 APEX Data for Zumilokibart in Moderate to Severe Atopic Dermatitis Transcript
Seeking Alpha • STOCK • 23/03/2026, 18:33:38
Apogee Therapeutics: Two Shots A Year, One Shot At Disruption
Seeking Alpha • STOCK • 23/03/2026, 18:12:56
Apogee Therapeutics, Inc. Announces Proposed $300 Million Underwritten Public Offering
GlobeNewsWire • STOCK • 23/03/2026, 17:01:00